Looking For A Buyer, Savient Talks Krystexxa Price & Gears Up For Launch
Executive Summary
On the prowl for a buyer after the approval of Krystexxa for refractory gout, Savient Pharmaceuticals assured investors that they have enough product supply to launch by year-end and that it will set a premium price, though it was vague on when it will commit to an exact figure.
You may also be interested in...
Savient Seeks Europe Partner For Gout Drug Krystexxa After CHMP Boost
With other companies struggling to develop new gout therapies, Savient is hoping to develop a partnering strategy for Krystexxa in markets outside the U.S. as well as broaden use of the injectable biologic in different categories of patients.
Business & Finance News, In Brief
Generics Weigh On AstraZeneca Q3
Business & Finance News, In Brief
Generics Weigh On AstraZeneca Q3